Cover Image
Market Research Report
Product code
995541

Global Anti-obesity Drugs Market 2021-2025

Published: | TechNavio (Infiniti Research Ltd.) | 120 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global Anti-obesity Drugs Market 2021-2025
Published: March 5, 2021
TechNavio (Infiniti Research Ltd.)
Content info: 120 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Technavio has been monitoring the anti-obesity drugs market and it is poised to grow by $ 454.51 mn during 2021-2025 decelerate at a CAGR of 5% during the forecast period. Our reports on anti-obesity drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the limited number of approved drugs and use of bariatric surgery limited for morbid obesity. In addition, limited number of approved drugs is anticipated to boost the growth of the market as well.

The anti-obesity drugs market analysis includes type segment and geographical landscapes.

Technavio's anti-obesity drugs market is segmented as below:

By Type

  • class III anti-obesity drugs
  • class II anti-obesity drugs
  • class I anti-obesity drugs

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing obese population as one of the prime reasons driving the anti-obesity drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on anti-obesity drugs market covers the following areas:

  • Anti-obesity drugs market sizing
  • Anti-obesity drugs market forecast
  • Anti-obesity drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-obesity drugs market vendors that include Bausch Health Companies Inc., Currax Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., Gelesis Inc., GlaxoSmithKline Plc, Novo Nordisk AS, RECORDATI S.p.A., Rhythm Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and VIVUS Inc.. Also, the anti-obesity drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents
Product Code: IRTNTR70300

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Class III anti-obesity drugs - Market size and forecast 2020-2025
  • Class II anti-obesity drugs - Market size and forecast 2020-2025
  • Class I anti-obesity drugs - Market size and forecast 2020-2025
  • Market opportunity by Type

Market segmentation by Mechanism of Action

  • Market segments
  • Centrally acting anti-obesity drugs
  • Peripherally acting anti-obesity drugs
  • Other anti-obesity drugs

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Bausch Health Companies Inc.
  • Currax Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd.
  • Gelesis Inc.
  • GlaxoSmithKline Plc
  • Novo Nordisk AS
  • RECORDATI S.p.A.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Class III anti-obesity drugs - Market size and forecast 2020-2025 ($ million)
  • 22: Class III anti-obesity drugs - Year-over-year growth 2020-2025 (%)
  • 23: Class II anti-obesity drugs - Market size and forecast 2020-2025 ($ million)
  • 24: Class II anti-obesity drugs - Year-over-year growth 2020-2025 (%)
  • 25: Class I anti-obesity drugs - Market size and forecast 2020-2025 ($ million)
  • 26: Class I anti-obesity drugs - Year-over-year growth 2020-2025 (%)
  • 27: Customer landscape
  • 28: Impact of drivers and challenges
  • 29: Vendor landscape
  • 30: Landscape disruption
  • 31: Industry risks
  • 32: Vendors covered
  • 33: Market positioning of vendors
  • 34: Bausch Health Companies Inc. - Overview
  • 35: Bausch Health Companies Inc. - Business segments
  • 36: Bausch Health Companies Inc. - Key offerings
  • 37: Bausch Health Companies Inc. - Key customers
  • 38: Bausch Health Companies Inc. - Segment focus
  • 39: Currax Pharmaceuticals LLC - Overview
  • 40: Currax Pharmaceuticals LLC - Product and service
  • 41: Currax Pharmaceuticals LLC - Key offerings
  • 42: Currax Pharmaceuticals LLC - Key customers
  • 43: Currax Pharmaceuticals LLC - Segment focus
  • 44: F. Hoffmann-La Roche Ltd. - Overview
  • 45: F. Hoffmann-La Roche Ltd. - Business segments
  • 46: F. Hoffmann-La Roche Ltd. - Key offerings
  • 47: F. Hoffmann-La Roche Ltd. - Key customers
  • 48: F. Hoffmann-La Roche Ltd. - Segment focus
  • 49: Gelesis Inc. - Overview
  • 50: Gelesis Inc. - Product and service
  • 51: Gelesis Inc. - Key offerings
  • 52: Gelesis Inc. - Key customers
  • 53: Gelesis Inc. - Segment focus
  • 54: GlaxoSmithKline Plc - Overview
  • 55: GlaxoSmithKline Plc - Business segments
  • 56: GlaxoSmithKline Plc - Key offerings
  • 57: GlaxoSmithKline Plc - Key customers
  • 58: GlaxoSmithKline Plc - Segment focus
  • 59: Novo Nordisk AS - Overview
  • 60: Novo Nordisk AS - Business segments
  • 61: Novo Nordisk AS - Key offerings
  • 62: Novo Nordisk AS - Key customers
  • 63: Novo Nordisk AS - Segment focus
  • 64: RECORDATI S.p.A. - Overview
  • 65: RECORDATI S.p.A. - Business segments
  • 66: RECORDATI S.p.A. - Key offerings
  • 67: RECORDATI S.p.A. - Key customers
  • 68: RECORDATI S.p.A. - Segment focus
  • 69: Rhythm Pharmaceuticals, Inc. - Overview
  • 70: Rhythm Pharmaceuticals, Inc. - Business segments
  • 71: Rhythm Pharmaceuticals, Inc. - Key offerings
  • 72: Rhythm Pharmaceuticals, Inc. - Key customers
  • 73: Rhythm Pharmaceuticals, Inc. - Segment focus
  • 74: Teva Pharmaceutical Industries Ltd. - Overview
  • 75: Teva Pharmaceutical Industries Ltd. - Business segments
  • 76: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 77: Teva Pharmaceutical Industries Ltd. - Key customers
  • 78: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 79: VIVUS Inc. - Overview
  • 80: VIVUS Inc. - Business segments
  • 81: VIVUS Inc. - Key offerings
  • 82: VIVUS Inc. - Key customers
  • 83: VIVUS Inc. - Segment focus
  • 84: Currency conversion rates for US$
  • 85: Research Methodology
  • 86: Validation techniques employed for market sizing
  • 87: Information sources
  • 88: List of abbreviations